Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.

Cai X, Gao X, Yang W, Ji L

Expert opinion on pharmacotherapy5 Nov 2017Cited by 17 (Europe PMC)

PMID29090600DOI10.1080/14656566.2017.1400011PepBankPUB-29090600

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials in type 2 diabetes, IDegLira (insulin degludec plus liraglutide) lowered HbA1c by 1.89% from baseline.
In plain wordsIn trials of people with type 2 diabetes, the insulin degludec plus liraglutide product IDegLira lowered HbA1c by 1.89% from baseline.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline with IDegLira
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
absolute HbA1c change
−1.89%
IDegLira
Source sentences
Summary
the absolute HbA1c change after IDegLira treatment was -1.89% with significance (95% CI, -2.04% to -1.73%, p < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included.
Summary · context
Eight trials were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2909060001
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials in type 2 diabetes, body weight did not change significantly from baseline with IDegLira (insulin degludec plus liraglutide).
In plain wordsIn trials of people with type 2 diabetes, body weight did not change significantly with the insulin degludec plus liraglutide product IDegLira.
Peptide
Liraglutide
Outcome
No significant changeBody weight change from baseline with IDegLira
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
weighted mean difference
−0.81 kg
IDegLira
Source sentences
Summary
but the absolute weight change after IDegLira treatment was not significantly changed (WMD, -0.81 kg; 95% CI, -3.26 to 1.65 kg, p = 0.52).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included.
Summary · context
Eight trials were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2909060002
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials in type 2 diabetes, HbA1c change did not differ significantly between IDegLira and IGlarLixi.
In plain wordsIn trials of people with type 2 diabetes, the two insulin plus GLP-1 products lowered HbA1c by similar amounts.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change, IGlarLixi versus IDegLira
Study
n: not reported in source
Comparator
IGlarLixi
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Comparisons between IGlarLixi treatment and IDegLira treatment indicated no significant differences between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included.
Summary · context
Eight trials were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2909060003
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of randomized trials in type 2 diabetes, body weight change did not differ significantly between IDegLira and IGlarLixi.
In plain wordsIn trials of people with type 2 diabetes, the two insulin plus GLP-1 products changed body weight by similar amounts.
Peptide
Liraglutide
Outcome
No significant changeBody weight change, IGlarLixi versus IDegLira
Study
n: not reported in source
Comparator
IGlarLixi
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The absolute weight change after IGlarLixi treatment significantly decreased (weighted mean difference (WMD), -0.62 kg; 95% CI, -0.93 to -0.31 kg, p = < 0.01), but the absolute weight change after IDegLira treatment was not significantly changed (WMD, -0.81 kg; 95% CI, -3.26 to 1.65 kg, p = 0.52). T…
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included.
Summary · context
Eight trials were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2909060004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.